Leerink Partnrs Estimates Envista’s Q3 Earnings (NYSE:NVST)

Envista Holdings Co. (NYSE:NVST) – Equities researchers at Leerink Partnrs cut their Q3 2025 earnings per share estimates for shares of Envista in a report released on Wednesday, February 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $0.26 per share for the quarter, down from their prior estimate of $0.30. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Envista’s current full-year earnings is $0.72 per share. Leerink Partnrs also issued estimates for Envista’s Q4 2025 earnings at $0.29 EPS, FY2025 earnings at $0.98 EPS and FY2026 earnings at $1.27 EPS.

Envista (NYSE:NVST) last issued its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%.

A number of other brokerages also recently issued reports on NVST. Mizuho began coverage on shares of Envista in a report on Wednesday, December 4th. They issued an “underperform” rating and a $20.00 price target on the stock. Wells Fargo & Company lifted their target price on Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a report on Thursday. Robert W. Baird increased their price target on Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, October 31st. Piper Sandler lifted their price objective on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Finally, Leerink Partners upgraded Envista from an “underperform” rating to a “market perform” rating and increased their target price for the company from $16.00 to $23.00 in a research report on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $20.21.

Envista Trading Down 2.4 %

Envista stock opened at $21.27 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.08 and a quick ratio of 1.77. The firm’s 50 day moving average price is $19.96 and its 200-day moving average price is $19.12. Envista has a 1 year low of $15.15 and a 1 year high of $23.06. The stock has a market cap of $3.66 billion, a P/E ratio of -2.74, a PEG ratio of 1.82 and a beta of 1.34.

Hedge Funds Weigh In On Envista

A number of large investors have recently bought and sold shares of the business. Pzena Investment Management LLC bought a new stake in Envista during the 4th quarter valued at about $16,979,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Envista by 17.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 42,057 shares of the company’s stock worth $811,000 after acquiring an additional 6,320 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Envista during the fourth quarter valued at approximately $10,808,000. Proficio Capital Partners LLC purchased a new stake in shares of Envista in the fourth quarter valued at approximately $358,000. Finally, M&T Bank Corp grew its stake in Envista by 4.2% in the fourth quarter. M&T Bank Corp now owns 16,621 shares of the company’s stock worth $320,000 after purchasing an additional 676 shares in the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.